| | Baroda BNP Paribas Health and Wellness Fund | |
(An open ended equity scheme investing in Pharma and Healthcare sector)
Investors understand that their
Benchmark riskometer is at Very High risk.
^^Riskometer For Scheme: basis it’s portfolio, ^Riskometer For Benchmark (BSE Healthcare TRI): basis it’s constituents; as on Oct 31, 2026
| Date of allotment | : June 27, 2025 |
| Tier 1 Benchmark | : BSE Healthcare TRI |
| NAV as on October 30, 2026: | |
| NAV/Unit | Regular Plan (In Rs.) | Direct Plan (In Rs.) |
| IDCW | 10.5641 | 10.8071 |
| Growth | 10.5641 | 10.8071 |
| Monthly AUM as on Oct 31, 2026 (Rs. in Cr.) | : 477.05 |
| Monthly AAUM as on Oct 31, 2026 (Rs. in Cr.) | : 468.39 |
| Fund Manager | Total Experience | Managing Since |
| Mr. Rohan Korde | 21 years | 01May--26 |
| Mr. Ankeet Pandya | 11 Years | 10-Jul-26 |
Lumpsum Amount:
Rs. 1000 and in multiples of Re. 1 thereafter
Additional Purchase Amount:
Rs. 1000 and in multiples of Re. 1 thereafter
Systematic Investment Plan (SIP) Amount:
(i) Daily, Weekly, Monthly SIP: Rs. 500/- and in
multiples of Re. 1/- thereafter; (ii) Quarterly SIP:
Rs. 1500/- and in multiples of Re. 1/- thereafter.
Exit Load:
• Redemption/ switch out of units upto
10% of the units allotted before 1 year from date of
allotment- Exit load -NIL.
• For redemption/switch out of units above 10%
of units allotted within 1 year from the date of
allotment 1.00% of applicable NAV.
• For redemption/switch out of units after 1 year
from the date of allotment-Nil.
For detailed load structure please refer Scheme
Information Document.
| Regular | Direct | ||
| Total Expense Ratio (Weighted TER) | : | 2.45% | 1.22% |
| Base Expense Ratio (as on October 31, 2026) | : | 2.09% | 1.04% |
| Standard Deviation (%) | : | 13.25 |
| Beta | : | 0.84 |
| Sharpe Ratio (%) | : | 0.28 |
| Information Ratio | : | -0.93 |
| Large Cap | : | 32.12 |
| Mid Cap | : | 46.12 |
| Small Cap | : | 18.78 |
| Cash | : | 2.98 |
| Compounded Annualised Returns | Scheme Returns % Regular | Scheme Returns % Direct | Benchmark Returns % |
| Last 1 year | 9.46 | 11.26 | 13.22 |
| Last 3 years | N.A. | N.A. | N.A. |
| Last 5 years | N.A. | N.A. | N.A. |
| Since Inception | 4.17 | 5.95 | 10.87 |
**Scheme Inception Date (Regular Plan): 27-Jun-25. Past performance may or may not be sustained in the future and does not
guarantee future returns. Performance data is provided for the Growth Option. Returns do
not take into account load and taxes, if any, and different plans may have a different expense
structure. Returns for periods exceeding one year are compounded annualised. Scheme
performance is calculated based on the NAV as of the last day of the month preceding the
date of publication of this factsheet. Where the commencement or end date of the relevant
period falls on a non-business day, the NAV of the immediately preceding business day
has been considered for the purpose of return calculation. Exit load, if any, has not been
considered while computing performance. Click here for the performance
of other schemes managed by the Fund Manager(s). Data as on October 30, 2026
*Investors should consult their financial advisers if in doubt about whether the product is
suitable for them.
| Holdings | % to Net Assets | |
| 1. | Sun Pharmaceutical Industries Limited | 8.58 |
| 2. | Divis Laboratories Ltd | 8.41 |
| 3. | Torrent Pharmaceuticals Ltd | 7.74 |
| 4. | Laurus Labs Limited | 7.56 |
| 5. | IPCA Laboratories Ltd | 6.06 |
| 6. | Lupin Ltd | 5.86 |
| 7. | Apollo Hospitals Enterprise Limited | 5.58 |
| 8. | Fortis Healthcare Ltd | 4.06 |
| 9. | Glenmark Pharmaceuticals Ltd | 3.13 |
| 10. | Aurobindo Pharma Ltd | 2.89 |
|
for Detailed Investment in Securities |
| Portfolio Turnover Ratio (Annualized) | |
| a) Equity Turnover | 0.63 |
| b) Gross Exposure Turnover | 0.64 |
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.
| | Thematic Concentration Risk | |
| | Market Risk (Volatility & Price Fluctuations) | |
| | Liquidity Risk | |
| | Credit and Counterparty Risk (Risk of Default) | |
| | Operational Risk (Risk of Trading or Backoffice or Administration Issues) |
Major Changes w.r.t previous month –
| Name of securities added | Name of securities deleted/reduced | Change in Weightage (%) |
| Divis Laboratories Ltd | 0.59 | |
| Laurus Labs Limited | 1.47 | |
| Lupin Ltd | 0.07 | |
| Apollo Hospitals Enterprise Limited | 0.30 | |
| Fortis Healthcare Ltd | 0.08 | |
| Glenmark Pharmaceuticals Ltd | 0.02 | |
| Torrent Pharmaceuticals Ltd | -0.14 | |
| IPCA Laboratories Ltd | -0.07 | |
| Aurobindo Pharma Ltd | -0.20 | |
| Dr. Lal Pathlabs Limited | -0.67 | |
| Mankind Pharma Limited | -1.25 |
| Change in | Sep 2026 | Oct 2026 |
| Regular | 2.26% | 2.45% |
| Direct | 1.21% | 1.22% |
No change
| Sr. No. | Important Weblinks | |
| 1 | Video Explainer | Click here for a video providing simplified explanation of the Fund Factsheet |
| 2 | Calculation/Methodology | Click here for various mathematical parameters and their respective calculation methodology/formulae |
| 3 | Detailed Risk Factors | Click here for various risk factors associated with the Scheme. |
| 4 | Scheme Information Document (SID) | Click here/Scan QR code for SID on the website ![]() |
| 5 | Investor Services | Click here for contact details for investor services. |
| 6 | Grievance submission and redressal | Click here to be directed to the grievance submission page. |
Additional Disclosure
Past performance may or may not be sustained in future and is not a guarantee of future returns. Returns do not take into account the load and taxes, if any. Different plans shall have a different expense structure. The above data assumes investments in Growth option for distributor/regular plan. Where returns are not available for a particular period, they have not been shown. *% CAGR Returns are computed after accounting for the cash flow by using the XIRR method. For further details on performance of the scheme and performance of other schemes managed by the Fund Manager, please refer to “Performance of Schemes”. Please note TRI indicates Total Return Index. Data as on October 30, 2026